1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)

Abstract

Delta-like ligand 3 (DLL3) is a promising therapeutic target highly expressed in SCLC and minimally expressed in normal tissues. AMG 757 is an HLE BiTE therapy that binds DLL3 on cancer cells and CD3 on T cells, resulting in redirected T cell-dependent killing of tumor cells. In phase I, AMG 757 every 2 wk was tolerable with encouraging efficacy up to 100 mg in SCLC.1,2 In early trials, programmed cell death-1 (PD-1) or ligand (PD-L1) antibodies provided efficacy in relapsed/refractory (RR) SCLC.